This bleeding risk was also discussed in the review. Hypertension being a coincident contributor to risk.
Unlike a gastrointestinal bleed, the consequences of a cerebral bleed, whether or not fatal, can be of a severity comparable to a cancer or a myocardial infarct in a risk/benefit evaluation. Estimates of additional risk in patients on aspirin are around one or two events per ten thousand (10,000) subject-years. The major factor in cerebral bleeding however is hypertension, and in an RCT of aspirin based on more than 18,000 hypertensive patients—all of whom were receiving ‘optimal’ antihypertensive treatment—there were no additional cerebral bleeds in patients randomised to aspirin.